A Snapshot of Neuropathic Pain Management: Prescribing Patterns and the Tolerance Challenge
A recent nationwide survey by the Spanish Pain Society reveals significant variability and partial adherence to international guidelines in the pharmacological management of neuropathic pain. The study, published in the European Journal of Pain, found that while gabapentinoids and certain antidepressants remain first-line choices, clinical decision-making heavily relies on personal experience. The research also quantifies, for the first time, clinicians’ widespread recognition of drug tolerance, typically emerging within 3–12 months of treatment, and highlights heterogeneous dosing practices that frequently deviate from recommended protocols.
Study Significance: For professionals in laboratory medicine and clinical chemistry, this survey underscores the critical role of therapeutic drug monitoring (TDM) and precise analytical methods in optimizing neuropathic pain treatment. The documented variability in dosing and the common development of tolerance point to a clear need for robust TDM protocols to guide dose escalation and drug switching, moving beyond reliance on clinical experience alone. This research directly informs the development of more standardized diagnostic algorithms and post-analytical interpretation to support personalized, evidence-based patient care.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
